Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: Cooperation of akt with raf/erk leads to p65 nuclear factor kB-mediated antiapoptosis involving c-IAP2

Blood

Volumn 98, Issue 8, 2001, Pages 2508-2517

  Gelfanov, Vasily M ^a   Burgess, Gem S ^a   Litz Jackson, Sara ^a   King, Alastair J ^a   Marshall, Mark S ^a   Nakshatri, Harikrishna ^a   Scott Boswell, H ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; PROTEIN TYROSINE KINASE; RAF PROTEIN; STAT5 PROTEIN; SYNAPTOTAGMIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL LYSATE; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0035889120     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2508     Document Type: Article

References (57)

1. Mandanas RA, Leibowitz DS, Gharehbaghi K, etal. Role of p21 ras in p210 BCR-ABL transformation of murine myeloid cells, Blood. 1993;82:1838-1847.
2. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein. Cell. 1993;75:175-185.
3. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE. Coupling between p210 BCR-ABL and Shc and Grb-2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to RAS activation pathway, J Exp Med. 1994; 179:167-175.
4. Matsuguchi T, Salgia R, Hallek M, et al, Shcphosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and Steel factor and is constitutively increased by p210 BCR-ABL. J Biol Chem. 1994;269:5016-5021.
5. , Puil L, Liu J, Gish R, et al. Bcr-Abl oncoproteins bind directly to activators of the ras signaling pathway. EMBO J. 1994;13:764-773.
6. Sawyers CL, McLaughlin J, Witte ON, Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the BCR/ABL oncogene. J Exp Med. 1995;181:307-313.
7. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Negative regulation of p120GAP GTPase promoting activity by p2lObcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med. 1994; 179:1855-1865.
8. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC, Activation of phosphatidylinositol-3-kinase in cells expressing ABL oncogene variants. Mol Cell Biol. 1991;11:1107-1113.
9. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.
10. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3-kinase/akt-dependent pathway. EMBO J. 1997;16:6151 -6161.
11. Jain SK, Langdon WY, Varticovski L. Tyrosine phosphorylation of p120 Cbl in BCR/ABL transformed hematopoietic cells mediates enhanced association with phosphatidylinositol-3-kinase. Oncogene. 1997;14:2217-2228.
12. Ilarla RL Jr, Van Etten RA. P210 and p190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704-31710.
13. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996;183:811-820.
14. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology SH3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999; 189:1229-1242.
15. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. Stat 5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000;95:2118-2125.
16. Skorski T, Nieborowska-Skorska M, Szczylik C, etal. C-Raf-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res. 1995;55:2275-2278.
17. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15:2333-2342.
18. Salomoni P, Wasik MA, Riedel RE, et al. Expression of constitutively active raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med. 1998;187:1995-2007.
19. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and raf. Mol Cell Biol. 2000;20:1179-1186.
20. Rodriguez-Viciana P, Warne F, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of PI-3-kinase by interaction with ras and by point mutation. EMBO J. 1996; 15:2442-2451.
21. Rordorf-Nikolic T, van Horn DJ, Chen D, White MF, Backer JM. Regulation of Pl-3-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85kd regulatory subunit. J Biol Chem. 1995;270:3662-3666.
22. KlippelA, Escobedo JA, Hu Q, Williams LT.A region of the 85 kilodalton subunit of PI-3-kinase binds the 110 kd catalytic subunit in vivo. Mol Cell Biol. 1993;13:5560-5566.
23. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NFkB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968-981.
24. Daley GQ, van Etten RA, Baltimore D. Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia specific p210 BCR/ABL protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.
25. Boudewijn M, Burgering T, Coffer PJ. Protein kinase B (c-akt) in phosphatidylinositol-3-OH kinase signal transduction, Nature. 1996;376:599-602.
26. Diaz B, Barnard D, Filson A, MacDonald S, King A, Marshall M. Phosphorylation of raf-1 serine 338, serine 339 is an essential event for ras-dependent activation and biological signaling. Mol Cell Biol. 1997;17:4509-4516.
27. Boswell HS, Harrington MA, Burgess GS, et al. A mutant RAS gene acts through protein kinase C to augment interleukin-3-dependent proliferation in a fastidious immortal myeloid cell line. Leukemia. 1989;3:662-668.
28. Hehner SP, Heinrich M, Bork PM, et al. Sesquiterpene lactones specifically inhibit activation of NFκB by preventing the degradation of IKBα and IKBβ. J Biol Chem. 1998;273:1288-1297.
29. Williamson EA, Burgess GS, Eder P, Litz-Jackson S, Boswell HS. Cyclic AMP negatively controls c-myc transcription and G 1 cell cycle progression in p210 BCR-ABL transformed cells: inhibitory activity exerted through cyclin D1 and cdk4. Leukemia. 1997;11:73-85.
30. Burgess GS, Williamson EA, Cripe LD, et al. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998;92:2450-2460.
31. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through Stat5. Blood. 2000;96:2269-2276.
32. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901-910.
33. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-myc. Science. 1994;264:424-427.
34. Afar DE, McLaughlin J, Sherr CJ, Witte ON, Roussel MF. Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci U S A. 1995;92:9540-9544.
35. Raitano AB, Halpern JR, Hambuch RM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11746-11750.
36. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The Tel/PDGFβR fusion in CMML is a transforming protein which self-associates and activates PDGFβR kinase- dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14845-14850.
37. Palmer AM, Mahajan S, Frank DA, Druker BJ, Gilliland DG, Carroll M. The Tel/PDGFβR fusion protein activates Stat1 and Stat5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol. 2000;28:584-593.
38. Levy DE, Gilliland DG. Divergent roles of Stat1 and Stat5 in malignancy as revealed by gene disruptions in mice. Oncogene. 2000;19:2502-2510.
39. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates Stat5 and MAP kinase and introduces autonomous growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
40. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.
41. Oda T, Tamura S, Matsuguchi T, Griffin JD, Druker BJ. The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia. 1995;9:295-301.
42. Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ. Interactions of cbl with Bcr-Abl and CrkL in Bcr-Abl-transformed myeloid cells. J Biol Chem. 1997;272:16170-16175.
43. Heaney C, Kolibaba K, Bhat A, et al. Direct binding of CrkL to BCR-ABL is not required for BCR-ABL transformation. Blood. 1997;89:297-306.
44. Sexl V, Piekorz R, Marigga R, et al. Stat 5a/b contribute to interleukin-7- induced B cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood. 2000;96:2277-2283.
45. Willamson EA, Burgess GS, Rizzo MT, Litz-Jackson S, Kraft AS, Boswell HS. Role for Pl-3-kinase in c-myc expression by p210 Bcr-Abl. Exp Hematol. 1996;24:464a.
46. Cortez D, Stoiak G, Pierce JH, PendergastAM. The Bcr-Abl tyrosine kinase inhibits apoptosis by activating a ras-dependent signaling pathway. Oncogene. 1996;13:2589-2594.
47. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-lAP2 is under NFkB control. Proc Natl Acad Sci U S A. 1997;94:10057-10062.
48. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NFkB antiapoptosis. Induction of TRAF-1 and TRAF-2 and clAP-1 and clAP-2 to suppress caspase 8 activation. Science. 1998;281:1680-1683.
49. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival bcl-2 homologue Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNF-alpha-induced apoptosis. Genes Dev. 1999;13:382-387.
50. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286:1358-1362.
51. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NFkB activation by tumor necrosis factor requires the AKT serine threonine kinase. Nature. 1999;401:82-85.
52. Romashkova JA, Makarov SS. NFkB is a target of AKT in antiapoptotic PDGF signaling. Nature. 1999;401:86-90.
53. Madrid LV, Wang CY, Guthridge DC, Schottelius AJG, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the relA/p65 subunit of NFkB. Mol Cell Biol. 2000;20:1626-1638.
54. Kane LP, Shapiro VS, Stokoe D, Weiss J. Induction of NFκB by the Aκt/PKB kinase. Curr Biol. 1999;9:601-604.
55. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol. 1998; 18:790-798.
56. Lin SC, Wortis HH, Stavnezer J. The ability of CD40L but not lipopolysaccharide to initiate immunoglobulin switching to IgG1 is explained by differential induction of NFκB/rel proteins. Mol Cell Biol. 1998; 18:5523-5532.
57. Algarte M, Kwon H, Genin P, Hiscott J. Identification by in vivo genomic footprinting of a transcriptional switch containing NFkB and Spl that regulates the IKBα promoter. Mol Cell Biol. 1999;19:6140-6153.